Loading clinical trials...
Loading clinical trials...
Phase 2 Study of the Treatment of Antiretroviral Treatment-Experienced Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) vs. a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination With Background ART.
The purpose of this study is to evaluate the non-inferiority of ritonavir-boosted GS-9137 relative to a ritonavir-boosted Comparator Protease Inhibitor when used as part of combination antiretroviral regimens in subjects who have failed, or are failing, protease inhibitor therapy.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Beverly Hills, California, United States
Fountain Valley, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
Oakland, California, United States
San Diego, California, United States
San Francisco, California, United States
Start Date
February 1, 2006
Primary Completion Date
June 1, 2007
Completion Date
July 1, 2007
Last Updated
July 29, 2008
278
ACTUAL participants
GS-9137 - A Novel HIV-1 Integrase Inhibitor
DRUG
Lead Sponsor
Gilead Sciences
NCT07071623
NCT01875588
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04929028